Published: March 4th 2025 | Updated: March 5th 2025 First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1 Rose McNulty Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (...
{ "@babel/traverse": "^7.24.7", @@ -459,6 +271,7 @@ "version": "7.24.7", "resolved": "https://registry.npmjs.org/@babel/helper-split-export-declaration/-/helper-split-export-declaration-7.24.7.tgz", "integrity": "sha512-oy5V7pD+UvfkEATUKvIjvIAH/xCzfsFVw7ygW2SI6NClZzquT+...
ie;background-size:28px 16px;height:16px;width:28px}.mcs-ipa{display:none}.mw-body-content{counter-reset:mw-numbered-ext-link}.mw-body-content a[rel~='mw:ExtLink']:empty:after{content:'[' counter(mw-numbered-ext-link) ']';counter-increment:mw-numbered-ext-link}.content figure img,...
ie;background-image:linear-gradient(transparent,transparent),url("data:image/svg+xml,%3C%3Fxml version=%221.0%22 encoding=%22UTF-8%22%3F%3E%3Csvg xmlns=%22http://www.w3.org/2000/svg%22 width=%2210%22 height=%2210%22%3E%3Cpath fill=%22%23fff%22 stroke=%22%2336c%22 d=%22M.5 3....